中国P站

Chronic Rhinosinusitis; Nasal Polyps; Endoscopic Sinus Surgery; Biologics; Eosinophilic Inflammation; Sinonasal Microbiome; Quality of Life; Treatment Recurrence; Endotypes; Personalized Medicine

Introduction

Chronic rhinosinusitis (CRS) represents a persistent inflammatory condition affecting the nasal and sinus mucosa, frequently presenting with nasal polyps, a subtype known as CRSwNP [1].

The primary therapeutic approach for CRSwNP that is refractory to medical management is endoscopic sinus surgery (ESS), which aims to enhance sinonasal drainage and diminish inflammation [1].

Recent investigations have increasingly emphasized the importance of personalized treatment strategies, including the evaluation of biologics for severe eosinophilic CRSwNP and the refinement of surgical techniques to achieve superior outcomes and minimize recurrence [1].

Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps has undergone significant evolution over time. Current efforts are focused on precise surgical navigation, reducing tissue trauma during the procedure, and gaining a deeper understanding of the underlying pathophysiology to guide effective post-operative care [2].

The integration of advanced imaging modalities and refined surgical techniques is intended to optimize disease control and enhance the quality of life for patients suffering from this condition [2].

Nasal polyps are a defining characteristic of CRSwNP, arising from a complex inflammatory cascade that frequently involves eosinophils and a Th2-mediated immune response. A thorough comprehension of these underlying mechanisms is essential for the development of targeted therapies that extend beyond conventional surgical interventions, such as the utilization of biologics designed to address specific inflammatory pathways [3].

Biologics have emerged as a crucial treatment option for individuals with severe eosinophilic CRS with nasal polyps, offering a targeted therapeutic strategy to reduce polyp burden and alleviate sinonasal symptoms. The efficacy of these biological agents is often assessed in conjunction with the outcomes achieved through surgical interventions [4].

The role of the sinonasal microbiome in the pathogenesis of CRS and CRSwNP is gaining substantial recognition. Alterations in microbial balance, or dysbiosis, may contribute to chronic inflammation and the formation of nasal polyps. Investigating these complex interactions holds promise for the development of novel therapeutic approaches [5].

Assessing the quality of life experienced by patients is a critical component in the management of CRS. Endoscopic sinus surgery is designed to significantly improve patient-reported outcomes, and longitudinal studies have demonstrated sustained benefits following surgical intervention, although the potential for recurrence remains a notable consideration [6].

The recurrence of nasal polyps following endoscopic sinus surgery presents a common challenge in the long-term management of CRSwNP. Identifying the factors that contribute to this recurrence, such as persistent inflammation or the presence of specific underlying endotypes, is vital for optimizing management strategies and considering the judicious use of adjuvant therapies [7].

The endotypic classification of chronic rhinosinusitis, particularly the presence of eosinophilia (CRSwNP-E), plays a pivotal role in determining treatment response. Distinguishing between eosinophilic and non-eosinophilic CRSwNP is fundamental to guiding both surgical and medical interventions, including the appropriate application of biologic therapies [8].

Adjunctive medical therapy administered post-operatively after ESS for CRSwNP is indispensable for achieving long-term disease control. Therapeutic interventions such as nasal saline irrigations, topical corticosteroids, and, in specific instances, oral corticosteroids or biologics, are employed to sustain surgical success and prevent disease recurrence [9].

A multidisciplinary approach to the management of CRSwNP, which integrates the expertise of ENT specialists, allergists, and pulmonologists, provides a comprehensive and holistic strategy. This collaborative effort is indispensable for effectively managing complex patient cases, addressing co-existing comorbidities, and optimizing overall patient outcomes [10].

Description

Chronic rhinosinusitis (CRS) is characterized by persistent inflammation of the nasal and sinus lining, frequently complicated by the presence of nasal polyps (CRSwNP). Endoscopic sinus surgery (ESS) is considered a fundamental treatment for CRSwNP that does not respond to other therapies, aiming to improve the drainage of the sinuses and reduce inflammation [1].

Emerging research is concentrating on personalized treatment plans, including the role of biologic therapies for severe eosinophilic CRSwNP and the refinement of surgical techniques to enhance outcomes and decrease the incidence of recurrence [1].

The field of endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps has seen considerable advancements. The current focus is on achieving high precision in surgical navigation, minimizing tissue damage, and deepening the understanding of the underlying pathophysiology to inform post-operative care strategies [2].

The utilization of sophisticated imaging technologies and advanced surgical methods is intended to optimize the control of the disease and improve the quality of life for patients [2].

Nasal polyps are a key clinical manifestation of CRSwNP, driven by a complex inflammatory process that often involves eosinophils and a Th2-type immune response. A comprehensive understanding of these pathomechanisms is critical for developing targeted treatments that go beyond traditional surgical interventions, such as employing biologics that modulate specific inflammatory pathways [3].

Biologic agents have emerged as a significant therapeutic modality for patients with severe eosinophilic CRS and nasal polyps, providing a targeted approach to reduce polyp size and improve sinonasal symptoms. Their clinical effectiveness is frequently assessed in the context of surgical outcomes [4].

The contribution of the sinonasal microbiome to the development and progression of CRS and CRSwNP is increasingly acknowledged. Imbalances in the microbial community, known as dysbiosis, may play a role in chronic inflammation and the formation of polyps. Insights gained from studying these interactions could pave the way for innovative therapeutic strategies [5].

The assessment of patient quality of life is of utmost importance in the management of CRS. Endoscopic sinus surgery is designed to lead to significant improvements in patient-reported outcomes, with longitudinal studies indicating sustained benefits after surgery, although the possibility of recurrence remains a pertinent concern [6].

Recurrence of nasal polyps after endoscopic sinus surgery is a frequently encountered challenge. Understanding the factors that predispose to recurrence, such as ongoing inflammation or specific underlying endotypes, is crucial for optimizing long-term management and considering the use of adjuvant therapies [7].

The endotype of chronic rhinosinusitis, specifically the presence of eosinophilia (CRSwNP-E), is a critical determinant of treatment response. Differentiating between eosinophilic and non-eosinophilic CRSwNP is essential for guiding appropriate surgical and medical interventions, including the selection of biologic therapies [8].

Adjunctive medical management following endoscopic sinus surgery for CRSwNP is vital for maintaining long-term disease control. Treatment strategies typically include nasal saline irrigations, topical corticosteroids, and, in certain cases, oral corticosteroids or biologics, all aimed at preserving surgical success and preventing recurrence [9].

A multidisciplinary approach to the management of CRSwNP, involving collaboration among ENT specialists, allergists, and pulmonologists, offers a comprehensive management strategy. This coordinated effort is essential for handling complex cases, addressing associated comorbidities, and achieving optimal patient outcomes [10].

Conclusion

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition treated with endoscopic sinus surgery (ESS). Advancements focus on personalized medicine, including biologics for severe eosinophilic CRSwNP, and refining surgical techniques to improve outcomes and reduce recurrence. The pathophysiology of nasal polyps involves eosinophilic and Th2-mediated inflammation, making targeted therapies like biologics crucial. Understanding the sinonasal microbiome and endotypes is key to management. Quality of life improvement is a primary goal of ESS, though recurrence remains a challenge requiring adjunctive medical therapies such as corticosteroids and biologics. A multidisciplinary approach is essential for comprehensive care.

References

1. Peter WH, Christos CB, Wytske JF. (2021) .Laryngoscope 131:e23742.

   , ,

2. Robert LPW, David WK, William BF. (2021) .Otolaryngol Clin North Am 54:205-219.

   , ,

3. Valerie JL, Carsten S, Bertrand JGP. (2022) .Allergy 77:1097-1114.

   , ,

4. Elina BG, Kian V, Sarah CL. (2023) .Curr Allergy Asthma Rep 23:15.

   , ,

5. Jose LD, Paula JR, David MP. (2022) .Front Cell Infect Microbiol 12:863581.

   , ,

6. Erin FO, Justin BB, Naren B. (2021) .JAMA Otolaryngol Head Neck Surg 147:341-348.

   , ,

7. Alina KD, Sujay VK, Jason PL. (2022) .Rhinology 60:174-185.

   , ,

8. Joanna MP, Mark WR, Richard JH. (2020) .Int Forum Allergy Rhinol 10:1039-1050.

   , ,

9. Kathleen BC, David AS, Peter SC. (2023) .Am J Rhinol Allergy 37:1-7.

   , ,

10. Philippe G, Christos CB, Wytske JF. (2024) .Rhinology 62:1-15.

    , ,